NIHR Signal: Long-term macrolide antibiotics reduce risk of exacerbations of bronchiectasis

NIHR Dissemination Centre
NIHR Dissemination Centre
Publication date:
31 October 2019


Expert commentary of 3 trials (n=341) states long-term macrolide therapy decreased frequency of exacerbations vs. placebo (incidence rate ratio 0.49, 95% CI 0.36 to 0.66); preventative antibiotics may be an option for more patients, but risk-benefit needs to be considered.